Literature DB >> 2175768

In vitro prostaglandin E2 production by glioblastoma cells and its effect on interleukin-2 activation of oncolytic lymphocytes.

Y Sawamura1, A C Diserens, N de Tribolet.   

Abstract

Glioblastoma cells constitutively produce various amounts of PGE2 (prostaglandin E2) in vitro. The amounts of PGE2 found in the conditioned medium of the glioblastoma cultures (less than 5 ng/ml) were not enough to inhibit the IL-2 (interleukin-2) activation of peripheral blood lymphocytes. However the amount of PGE2 produced by approximately 1 x 10(7) of the glioblastoma cells can be assumed to suppress the generation of IL-2-induced killing activity against glioblastoma cells.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2175768     DOI： 10.1007/BF02427832

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


  23 in total

Review 1.  Prostaglandins E as modulators of the immune response.

Authors:  S Chouaib; J H Bertoglio
Journal:  Lymphokine Res       Date:  1988

Review 2.  Regulation of the immune response by prostaglandins.

Authors:  J S Goodwin; J Ceuppens
Journal:  J Clin Immunol       Date:  1983-10       Impact factor: 8.317

3.  In vitro synthesis of prostaglandins and related lipids by populations of human peripheral blood mononuclear cells.

Authors:  M S Kennedy; J D Stobo; M E Goldyne
Journal:  Prostaglandins       Date:  1980-07

4.  Prostaglandin and thromboxane synthesis by human intracranial tumors.

Authors:  M G Castelli; C Chiabrando; R Fanelli; L Martelli; G Butti; P Gaetani; P Paoletti
Journal:  Cancer Res       Date:  1989-03-15       Impact factor: 12.701

5.  The glioblastoma-derived T cell suppressor factor/transforming growth factor-beta 2 inhibits T cell growth without affecting the interaction of interleukin 2 with its receptor.

Authors:  C Siepl; S Bodmer; K Frei; H R MacDonald; R De Martin; E Hofer; A Fontana
Journal:  Eur J Immunol       Date:  1988-04       Impact factor: 5.532

6.  In situ characterization, clonogenic potential, and antitumor cytolytic activity of T lymphocytes infiltrating human brain cancers.

Authors:  S Miescher; T L Whiteside; N de Tribolet; V von Fliedner
Journal:  J Neurosurg       Date:  1988-03       Impact factor: 5.115

7.  Penetration of recombinant interleukin-2 across the blood-cerebrospinal fluid barrier.

Authors:  S C Saris; S A Rosenberg; R B Friedman; J T Rubin; D Barba; E H Oldfield
Journal:  J Neurosurg       Date:  1988-07       Impact factor: 5.115

8.  Intratumoral LAK cell and interleukin-2 therapy of human gliomas.

Authors:  D Barba; S C Saris; C Holder; S A Rosenberg; E H Oldfield
Journal:  J Neurosurg       Date:  1989-02       Impact factor: 5.115

9.  Recombinant granulocyte-macrophage colony-stimulating factor down-regulates expression of IL-2 receptor on human mononuclear phagocytes by induction of prostaglandin E.

Authors:  W W Hancock; M E Pleau; L Kobzik
Journal:  J Immunol       Date:  1988-05-01       Impact factor: 5.422

10.  Prostaglandins from human T suppressor/cytotoxic cells modulate natural killer antibacterial activity.

Authors:  P Garcia-Peñarrubia; A D Bankhurst; F T Koster
Journal:  J Exp Med       Date:  1989-08-01       Impact factor: 14.307
View more
  19 in total

Review 1.  All in the head: obstacles for immune rejection of brain tumours.

Authors:  Paul R Walker; Thomas Calzascia; Pierre-Yves Dietrich
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

Review 2.  Immunotherapy of malignant gliomas using autologous and allogeneic tissue cells.

Authors:  F M Hofman; A Stathopoulos; C A Kruse; T C Chen; V E J C Schijns
Journal:  Anticancer Agents Med Chem       Date:  2010-07       Impact factor: 2.505

Review 3.  Recent advances in immunobiology of brain tumors.

Authors:  M Tada; N de Tribolet
Journal:  J Neurooncol       Date:  1993-09       Impact factor: 4.130

4.  Molecular mechanisms underlying gliomas and glioblastoma pathogenesis revealed by bioinformatics analysis of microarray data.

Authors:  Basavaraj Vastrad; Chanabasayya Vastrad; Ashok Godavarthi; Raghu Chandrashekar
Journal:  Med Oncol       Date:  2017-09-26       Impact factor: 3.064

Review 5.  Glioblastoma stem cells and stem cell-targeting immunotherapies.

Authors:  Rogelio Esparza; Tej D Azad; Abdullah H Feroze; Siddhartha S Mitra; Samuel H Cheshier
Journal:  J Neurooncol       Date:  2015-02-15       Impact factor: 4.130

6.  Influenza vaccine immunogenicity in patients with primary central nervous system malignancy.

Authors:  Roy E Strowd; Katrina Swett; Michele Harmon; Annette F Carter; Aurora Pop-Vicas; Michael Chan; Stephen B Tatter; Thomas Ellis; Maria Blevins; Kevin High; Glenn J Lesser
Journal:  Neuro Oncol       Date:  2014-04-08       Impact factor: 12.300

7.  A dominant-negative mutant of the platelet-derived growth factor A-chain increases survival of hamsters implanted intracerebrally with the highly invasive CxT24-neo3 glioblastoma cell.

Authors:  D M Kaetzel; J D Reid; N Pedigo; S G Zimmer; E R Boghaert
Journal:  J Neurooncol       Date:  1998-08       Impact factor: 4.130

8.  Eicosanoid production by brain tumours in vivo--evidence for intracranial compartmentation.

Authors:  V Walker; J D Pickard; P J Smythe; S Perry
Journal:  J Neurooncol       Date:  1991-12       Impact factor: 4.130

Review 9.  An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma.

Authors:  David A Reardon; Kai W Wucherpfennig; Gordon Freeman; Catherine J Wu; E Antonio Chiocca; Patrick Y Wen; William T Curry; Duane A Mitchell; Peter E Fecci; John H Sampson; Glenn Dranoff
Journal:  Expert Rev Vaccines       Date:  2013-06       Impact factor: 5.217

Review 10.  Immunotherapy advances for glioblastoma.

Authors:  David A Reardon; Gordon Freeman; Catherine Wu; E Antonio Chiocca; Kai W Wucherpfennig; Patrick Y Wen; Edward F Fritsch; William T Curry; John H Sampson; Glenn Dranoff
Journal:  Neuro Oncol       Date:  2014-09-04       Impact factor: 12.300
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.